This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
According to an article in Stat, AstraZeneca (NYSE: AZN) has paused the U.S. clinical trial of its coronavirus vaccine, AZD1222, after a serious possible adverse event arose in a patient enrolled in a clinical trial testing AZD122 in the U.K.
At this point, the nature of the adverse event is not known, and it isn’t clear whether it was caused by AZD122. The company is “working to expedite the review of the single event to minimize any potential impact on the trial timeline,” according to Stat. The participant is expected to recover.
In addition to the 30,000-participant U.S. study announced last week, AstraZeneca is also running clinical trials in the U.K., Brazil, and South Africa. The company plans to start studies in Japan and Russia as well. All told, the studies will enroll up to 50,000 participants globally.
It isn’t publicly known exactly how many patients have received AZD1222, but investors can get some clues from Moderna (NASDAQ: MRNA), which had enrolled 21,411 participants in its late-stage coronavirus vaccine clinical trial as of Friday. Meanwhile, vaccine collaborators Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) had enrolled 25,189 participants as of an update on Monday.
With that many people enrolled in coronavirus clinical trials, it’s highly likely that one of the participants would develop a serious illness unrelated to the vaccination. Of course, proving that it’s unrelated could be challenging and might only be possible by testing AZD122 on more participants. If the adverse event only occurs in one out of 50,000 participants, it’s either unrelated or a side effect with such a low incidence level that it’s a tolerable issue.
Shares of AstraZeneca were down 6.5% at 6:40 p.m. EDT in after-hours trading.
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
These stocks could rocket in a Post-COVID world (FREE STOCK REPORT)
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
Find out the names of our 3 Post COVID Stocks – For FREE!
*Returns as of 6/8/2020
More reading
- How to invest in coronavirus vaccine stocks
- In the race for a coronavirus vaccine, can there be multiple winners?
Brian Orelli, PhD has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post AstraZeneca coronavirus vaccine clinical trial paused appeared first on Motley Fool Australia.
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
from Motley Fool Australia https://ift.tt/2GM0061
Leave a Reply